Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma:a real-world study

作     者：Yuxiao Liu Xiaofan Guo Peijun Xu Yuning Song Jing Huang Xingyun Chen Wenbo Zhu Jihui Hao Song Gao Yuxiao Liu;Xiaofan Guo;Peijun Xu;Yuning Song;Jing Huang;Xingyun Chen;Wenbo Zhu;Jihui Hao;Song Gao

作者机构：Department of Pancreatic CancerTianjin Medical University Cancer Institute&HospitalNational Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjinTianjin's Clinical Research Center for CancerTianjin 300060China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2024年第21卷第9期

页      面：799-812页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This work was supported by the National Key Research and Development Program of China(Grant No.2021YFA1201100) the National Natural Science Foundation of China(Grant No.82072657) 

主　　题：Second-line chemotherapy advanced pancreatic adenocarcinoma 5-fluorouracil gemcitabine real-world study 

摘      要：Objective:Little progress has been made in recent years using first-line chemotherapy,including gemcitabine combined with nab-paclitaxel,FOLFIRINOX,and NALIRIFOX,for advanced pancreatic adenocarcinoma(APC).In addition,the optimal second-line chemotherapy regimen has not been *** study aimed to compare the effectiveness of different types of second-line chemotherapy for ***:Patients with APC who received first-line treatment from January 2008 to January 2021 were considered eligible for this retrospective *** primary and secondary endpoints were overall survival(OS)and progression-free survival(PFS),***:Four hundred and thirty-seven and 617 patients were treated with 5-fluorouracil-and gemcitabine-based chemotherapy as first-line treatment,*** and clinical features,except age and liver metastasis,were comparable between the two groups(P0.05).The median OS was 8.8 and 7.8 months in patients who received a 5-fluorouracil-and gemcitabine-based combined regimen for first-line therapy,respectively(HR=1.244,95%CI=1.090–1.419;P0.001).The median OS was 5.6 and 1.9 months in patients who received second-line chemotherapy and supportive care,respectively(HR=0.766,95%CI=0.677–0.867;P0.001).The median PFS was not significantly differently between gemcitabine or 5-fluorouracil monotherapy and combination ***:A 5-fluorouracil-or gemcitabine-based combined regimen was shown to be as effective as a single 5-fluorouracil or gemcitabine regimen as second-line therapy for patients with APC.